About sable bio

Sable Bio utilizes artificial intelligence to analyze extensive biomedical data for assessing drug target safety, providing quantified risk evaluations and recommended mitigations. The platform addresses the challenges of incomplete and outdated safety information, enabling more efficient and informed decision-making in drug development.

```xml <problem> Drug development faces challenges due to incomplete, outdated, and difficult-to-compile safety information regarding drug targets. Manual safety assessments are time-consuming, require specialized expertise, and struggle to keep pace with the volume of available data, potentially leading to overlooked safety risks. </problem> <solution> Sable Bio offers a platform that leverages artificial intelligence to provide comprehensive safety intelligence for drug targets, consolidating data from clinical, genetic, experimental, and textual sources. The platform delivers quantified risk evaluations and recommended mitigations tailored to specific modalities and modes of action. By offering up-to-date and easily digestible safety information, Sable Bio enables more efficient and informed decision-making in drug development, reducing the likelihood of safety-related failures in clinical trials. The platform's AI-augmented information extraction and curation, combined with customized toxicology-focused ontologies, ensures comprehensive safety coverage. </solution> <features> - Individual target safety assessment tailored to chosen modality and mode of action - Target selection ranking based on safety risks associated with the chosen modality - Quantified and interpretable probability scores for safety assessments - Recommended actions and mitigations for identified safety risks, including assays and experimental validations - Expansions by mechanism, target similarity, or potential off-target effects for less-studied targets - Flexible report configuration with experimental data integration - Secure addition of proprietary experimental, clinical, or text data - API access for programmatic access to reports and scores </features> <target_audience> Sable Bio's primary customers are drug discovery teams and pharmaceutical companies seeking to improve target safety assessment and reduce the risk of clinical trial failures. </target_audience> ```

What does sable bio do?

Where is sable bio located?

sable bio is based in London, United Kingdom.

When was sable bio founded?

sable bio was founded in 2023.

How much funding has sable bio raised?

sable bio has raised 1900000.

Location

London, United Kingdom

Founded

2023

Funding

1900000

Employees

9 employees

Major Investors

Episode 1

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

sable bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

sablebio.com 700+

Crunchbase

Founded 2023 – London, United Kingdom

Funding

Estimated Funding

$1M+

Major Investors

Episode 1

Team (5+)

No team information available.

Company Description

Problem

Drug development faces challenges due to incomplete, outdated, and difficult-to-compile safety information regarding drug targets. Manual safety assessments are time-consuming, require specialized expertise, and struggle to keep pace with the volume of available data, potentially leading to overlooked safety risks.

Solution

Sable Bio offers a platform that leverages artificial intelligence to provide comprehensive safety intelligence for drug targets, consolidating data from clinical, genetic, experimental, and textual sources. The platform delivers quantified risk evaluations and recommended mitigations tailored to specific modalities and modes of action. By offering up-to-date and easily digestible safety information, Sable Bio enables more efficient and informed decision-making in drug development, reducing the likelihood of safety-related failures in clinical trials. The platform's AI-augmented information extraction and curation, combined with customized toxicology-focused ontologies, ensures comprehensive safety coverage.

Features

Individual target safety assessment tailored to chosen modality and mode of action

Target selection ranking based on safety risks associated with the chosen modality

Quantified and interpretable probability scores for safety assessments

Recommended actions and mitigations for identified safety risks, including assays and experimental validations

Expansions by mechanism, target similarity, or potential off-target effects for less-studied targets

Flexible report configuration with experimental data integration

Secure addition of proprietary experimental, clinical, or text data

API access for programmatic access to reports and scores

Target Audience

Sable Bio's primary customers are drug discovery teams and pharmaceutical companies seeking to improve target safety assessment and reduce the risk of clinical trial failures.